Ilyang Pharm Stock Price To Book

007570 Stock   11,090  210.00  1.86%   
Ilyang Pharm fundamentals help investors to digest information that contributes to Ilyang Pharm's financial success or failures. It also enables traders to predict the movement of Ilyang Stock. The fundamental analysis module provides a way to measure Ilyang Pharm's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Ilyang Pharm stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Ilyang Pharm Company Price To Book Analysis

Ilyang Pharm's Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.

P/B

 = 

MV Per Share

BV Per Share

More About Price To Book | All Equity Analysis

Current Ilyang Pharm Price To Book

    
  1.56 X  
Most of Ilyang Pharm's fundamental indicators, such as Price To Book, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Ilyang Pharm is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Competition

Based on the latest financial disclosure, Ilyang Pharm has a Price To Book of 1.5581 times. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The price to book for all Republic of Korea stocks is notably lower than that of the firm.

Did you try this?

Run Equity Search Now

   

Equity Search

Search for actively traded equities including funds and ETFs from over 30 global markets
All  Next Launch Module

Ilyang Fundamentals

About Ilyang Pharm Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Ilyang Pharm's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ilyang Pharm using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ilyang Pharm based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Pair Trading with Ilyang Pharm

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Ilyang Pharm position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Ilyang Pharm will appreciate offsetting losses from the drop in the long position's value.

Moving together with Ilyang Stock

  0.78005935 Samsung ElectronicsPairCorr
  0.81005930 Samsung ElectronicsPairCorr
  0.67005490 POSCO HoldingsPairCorr

Moving against Ilyang Stock

  0.84035420 NaverPairCorr
  0.37011200 HMM CoPairCorr
The ability to find closely correlated positions to Ilyang Pharm could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Ilyang Pharm when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Ilyang Pharm - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Ilyang Pharm to buy it.
The correlation of Ilyang Pharm is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Ilyang Pharm moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Ilyang Pharm moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Ilyang Pharm can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Other Information on Investing in Ilyang Stock

Ilyang Pharm financial ratios help investors to determine whether Ilyang Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Ilyang with respect to the benefits of owning Ilyang Pharm security.